Invariantum

AI is rebuilding the senolytics field by solving three core failures: target identification, compound selectivity, and biomarker validation, transforming it from speculative to industrially viable.

The simulation layer will reprice drug discovery by replacing wet lab experiments with computation. Value accrues at the edges; the middle gets commoditized.